Akero Therapeutics Inc. (NASDAQ: AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced ...

The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy ...

European regulators have given their backing to a new eco-friendly inhaler that could help curb health care’s climate impact.

In this article, you’ll find some of the top content that was published on LCGC this week, including an ASMS 2025 retrospective and an overview of microplastic research.

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

With 1 August fast approaching, we expect the Trump administration to announce pharmaceutical tariffs soon. We anticipate an ...

Governor Glenn Youngkin spoke with 8News about AstraZeneca’s recent announcement to build their world’s-largest manufacturing ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.